Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The HIV attachment inhibitor led to sustained viral suppression and CD4 cell gains in people with extensive prior treatment.
Global study highlights the importance of prompt HIV treatment and viral suppression to prevent severe monkeypox.
A molecular decoy that neutralizes the SARS-CoV-2 virus by preventing it from latching onto cells protected mice against COVID-19.
People with greater immune resilience may be at lower risk for severe COVID-19, AIDS and recurrent skin cancer, NIAID grantees find.
People 65 and older and immunocompromised people can get a second bivalent booster; most unvaccinated people now need only one initial shot.
Most people who died of monkeypox in the United States had advanced HIV with a CD4 count below 50.
Herpes, HIV, Epstein-Barr and other viruses hang around, causing potential long-term health woes. Should long COVID surprise us?
More than a quarter of HIV-positive people with a CD4 count below 100 died from mpox complications.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.
People with suppressed HIV respond well to mRNA vaccines, but individuals with a low CD4 count may not be adequately protected.
The monoclonal antibody combo is used as pre-exposure prophylaxis for immunocompromised people who may not respond to COVID-19 vaccines.
Safety tips for the evolving pandemic. Plus: Which groups—such as those with cancer or HIV—are at higher risk for COVID-19 complications?
The update aims to help the public better protect themselves and understand their risk.
The good news is that only 4% of HIV-positive people experienced COVID breakthrough after vaccination.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.